- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
JPMorgan Chase Reduces Stake in Capricor Therapeutics
Biotechnology firm sees major institutional investor decrease position by 45%
Apr. 9, 2026 at 9:10am
Got story updates? Submit your updates here. ›
A reduction in a major investor's stake in Capricor Therapeutics signals potential shifts in the biotech firm's access to capital and institutional support.Beverly Hills TodayJPMorgan Chase & Co. has reduced its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 45% in the third quarter, according to a recent SEC filing. The financial services giant now owns 189,799 shares of the biotechnology company, down from 345,189 shares previously.
Why it matters
This decrease in JPMorgan's position represents a significant shift in institutional ownership of Capricor Therapeutics, a clinical-stage biotech focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. Changes in major investor holdings can impact a company's stock price and access to capital.
The details
According to the filing, JPMorgan Chase sold 155,390 shares of Capricor Therapeutics during the third quarter. The bank now owns approximately 0.42% of the company's outstanding stock, valued at $1.37 million as of the end of the reporting period.
- JPMorgan Chase reduced its Capricor Therapeutics stake in the third quarter of 2026.
- The SEC filing disclosing the decrease in position was published on April 9, 2026.
The players
JPMorgan Chase & Co.
A major global financial services firm and one of the largest institutional investors in the biotechnology sector.
Capricor Therapeutics, Inc.
A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases.
The takeaway
This reduction in JPMorgan Chase's Capricor Therapeutics stake suggests a shift in the investment firm's outlook on the biotech company's prospects, which could impact the stock's performance and the firm's access to capital going forward.
